Blood cancers include leukemia, lymphoma, and multiple myeloma.
Collectively, these cancers are the fifth most commonly occurring
cancers and the second leading cause of cancer death. Hematological
Cancer Therapeutics: Pipelines
and Competition provides a realistic assessment
of how newly-approved drugs and candidates in development will
impact this sector of the cancer treatment field within the next
decade. The report reviews the activities of the leading companies
in this arena and provides a market assessment for all companies
currently competing in or contemplating entering the field.
The major strides are being made in small specialist companies
with a broad range of compounds in Phases I– III. However,
the potential exists for large international companies to enter
the market as candidates from niche companies reach later stages
and prove useful in a broader context of cancer, as very frequently
is the case.
Indeed, many emerging novel agents, based on the identification
of genetic lesions and aberrant signaling pathways, promise to
improve upon standard therapies. Currently, therapy of blood
cancers is dominated by what hematologists call therapy ladders—sequential
uses of combination protocols consisting of drugs that have been
available for a long time and are frequently also used for the
treatment of solid tumors. However, this scenario will rapidly
become more diverse as new therapeutic options reach the market.
- Characterizes hematological cancers and the use of various
diagnostic technologies in conjunction with therapy selection
and disease monitoring.
- Reviews newly licensed or advanced clinical-stage compounds—antimetabolites,
inhibitors of DNA unwinding or transcription, or inhibitors
of kinase-modulated intracellular pathways—under development
at a multitude of small oncology companies for leukemias and
myelodysplastic syndromes, lymphomas (Hodgkin’s disease,
non–Hodgkin’s lymphoma, mantle cell lymphoma),
and multiple myeloma. Promising candidates include Celgene’s
Revlimid, a thalidomide analog in Phase III for myelodysplastic
syndrome and multiple myeloma, and Millennium Pharmaceutical’s
Velcade, a proteasome inhibitor, which has been gathering indications
for multiple myeloma since May 2003.
- Projects which market segments will experience the most
dynamic growth and evaluates market growth potential by cancer
- Weighs the potential of kinase-associated drugs to expand
the market for acute myeloid leukemia ( AML ).
Oncogenomics: The Future of Cancer Care
Cancer Diagnostics: Technology and Business Trends
About the Author
Hermann A.M. Mucke, Ph.D. spent 17 years in academia and industry
before he founded H.M. Pharma Consultancy (www.hmpharmacon.com)
in 2000 to become an independent pharmaceutical consultant, analyst
and science author. His last industry position was Vice President
R&D in a European pharmceutical company which he helped to
take public on the Frankfurt Stock Exchange in 1999. Since then,
Dr. Mucke, who holds a Ph.D. in biochemistry from the University
of Vienna (Austria) became a consultant and advisory board member
for several European and U.S. pharmaceutical companies, and a
regular reviewer of drugs and patents for Thomson Current Drugs
and Ashley Publications. He has served as an outside expert author
for CHI since 2004. Dr. Mucke is based in Vienna and can be reached
at firstname.lastname@example.org , or by fax at +43 1 494 9989.